Frontotemporal dementia - Articles - Page 3

Neurology/Psychiatric

NIH and DoD grants support Acurastem’s work in ALS and FTD

Jan. 31, 2024

Acurastem Inc. has raised nearly $7 million in grant funding from the National Institutes of Health (NIH) and the Department of Defense (DoD) to advance research in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Tree in the shape of human head losing leaves

Neurology/Psychiatric

Psilera selects behavioral variant frontotemporal dementia as lead indication for PSIL-006

Jan. 24, 2024

Psilera Inc. has selected behavioral variant frontotemporal dementia (FTD) as the lead...

Neurology/Psychiatric

Coya to expand development of COYA-302 beyond ALS

Jan. 17, 2024

Coya Therapeutics Inc. intends to expand proposed indications for COYA-302 beyond amyotrophic lateral sclerosis (ALS) to include frontotemporal dementia (FTD) and Parkinson’s disease.

Neurology/Psychiatric

Acurastem and Takeda sign license agreement for Acurastem’s PIKFYVE-targeted therapeutics

Sep. 26, 2023

Acurastem Inc. has entered into a license agreement with Takeda Pharmaceutical Company Ltd. to develop and commercialize Acurastem’s PIKFYVE-targeted therapeutics, including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of amyotrophic lateral sclerosis (ALS).

Neurology/Psychiatric

ATH-1105 protects from TDP-43 protein pathology in preclinical models

July 21, 2023

There is a strong link between the loss of TAR DNA-binding protein 43 (TDP-43) function and the development of frontotemporal dementia (FTD)...

Neurology/Psychiatric

[18F]ACI-19278 TDP-43 ligand shows high target engagement in brain imaging studies

July 20, 2023

Several neurodegenerative disorders have TAR DNA-binding protein 43 (TDP-43) inclusions as a pathological hallmark; thus, the development of PET tracers able to detect TDP-43 aggregates is essential to advance the diagnosis and treatment monitoring in diseases such as frontotemporal dementia, amyotrophic lateral sclerosis and others.

Neurology/Psychiatric

AGTC-601 gene therapy shows efficacy and safety in model of FTD with granulin mutations

May 23, 2023

Researchers from Applied Genetic Technologies Corp. have reported preclinical data for AGTC-601, a novel AAVrh10-granulin (GRN) gene therapy being developed for the treatment of frontotemporal dementia (FTD) with GRN mutations.

Elderly woman holding illustration of brain with missing puzzle piece

Neurology/Psychiatric

ARKD-104, a novel PGRN-enhancing compound to prevent frontotemporal dementia

April 4, 2023

Frontotemporal dementia (FTG-GRN) is a fatal neurodegenerative disease caused by heterozygous mutations in the GRN gene, encoding progranulin (PRGN). Researchers at Arkuda Therapeutics Inc. reported on ARKD-104, a novel potent orally bioavailable PGRN-enhancing compound that increased PRGN secretion and lysosomal granulins in multiple relevant cell lines.

Neurology/Psychiatric

Quralis announces program targeting UNC13A mis-splicing for neurodegenerative diseases

March 20, 2023

Quralis Corp. has launched a program that targets UNC13A mis-splicing, a critical genetic alteration...

Neurology/Psychiatric

Series A financing at Teitur Trophics to fund neurodegenerative disease pipeline

March 14, 2023

Teitur Trophics ApS, a spinout from Aarhus University seeded by the Bioinnovation Institute in 2020, has completed a €28 million (US$30.1 million) series A financing. Teitur has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function, and these peptides have the potential to treat a broad range of neurodegenerative diseases.

Articles Tagged with ''frontotemporal dementia''

NIH and DoD grants support Acurastem’s work in ALS and FTD

Psilera selects behavioral variant frontotemporal dementia as lead indication for PSIL-006

Coya to expand development of COYA-302 beyond ALS

Acurastem and Takeda sign license agreement for Acurastem’s PIKFYVE-targeted therapeutics

ATH-1105 protects from TDP-43 protein pathology in preclinical models

[18F]ACI-19278 TDP-43 ligand shows high target engagement in brain imaging studies

AGTC-601 gene therapy shows efficacy and safety in model of FTD with granulin mutations

ARKD-104, a novel PGRN-enhancing compound to prevent frontotemporal dementia

Quralis announces program targeting UNC13A mis-splicing for neurodegenerative diseases

Series A financing at Teitur Trophics to fund neurodegenerative disease pipeline

Today's news in brief

Hengrui discovers new Nav1.8 blockers

Hematopoietic stem cell research points to leukemia’s early roots

News in brief

Korsana boosts Alzheimer’s work with reverse merger, $380M financing